At a cross­roads, biotechs are pass­ing on re­verse merg­ers in 2025

Re­verse merg­ers have once again lost their lus­ter.

An al­ter­na­tive to go­ing pub­lic, re­verse merg­ers once car­ried a neg­a­tive stig­ma. But the fi­nanc­ing ve­hi­cle …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER